Internship
Develops technology for protein detection and measurement
$20 - $30/hr
Fremont, CA, USA
Upload your resume to see how it matches 10 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Alamar Biosciences focuses on the study of proteins, known as proteomics, to enhance disease detection and treatment. The company's main product, NULISA™, allows for the detection and measurement of proteins in the human body with high sensitivity and a wide range. This technology helps researchers and clinicians profile clinically relevant protein biomarkers, which are essential for developing new diagnostic tests and treatments. Alamar's ARGO™ system complements NULISA™ by providing a fully automated, high-throughput platform for precision proteomics. Unlike competitors, Alamar's technology simplifies the process, reducing the need for extensive technical expertise, making it more accessible to clients. The company's goal is to improve our understanding of proteins in health and disease, ultimately leading to better early detection and treatment options for various diseases.
Company Size
51-200
Company Stage
Grant
Total Funding
$232M
Headquarters
Hayward, California
Founded
2018
Help us improve and share your feedback! Did you find this helpful?
401(k) Company Match
401(k) Retirement Plan
Performance Bonus
Company Equity
Providing the largest and most comprehensive, high sensitivity, protein biomarker analysis to advance pre-clinical researchFREMONT, Calif., March 24, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the launch of the NULISAseq Mouse Panel 120, an innovative biomarker profiling solution that provides the most comprehensive coverage of protein targets for expression analysis in mouse models. Designed to facilitate biomedical research and pre-clinical development studies, this cutting-edge panel analyzes 120 proteins covering key pathways in inflammation, neurodegeneration and immuno-oncology."The NULISAseq Mouse Panel 120 encompasses an unparalleled selection of proteins essential for studying key biological pathways in pre-clinical models," said Yuling Luo, Ph.D., Founder, Chairman and CEO of Alamar Biosciences. "This robust panel is designed specifically for mouse models enabling researchers to gain valuable insights into disease mechanisms and therapeutic efficacy."With the broadest coverage of mouse protein targets, the NULISAseq Mouse Panel 120 is the only multiplex panel to include a specific focus on neurology content. This is crucial for researchers studying neurodegenerative diseases and the neurological effects of potential treatments."I'm excited to incorporate the NULISAseq Mouse Panel 120 panel into my research studies." said Cheryl Wellington, Ph.D., Professor, Department of Pathology and Laboratory Medicine at University of British Columbia. "This state-of-the art panel provides me with the broadest view of neuro-physiology and has the potential to uncover new insights into the mechanisms of dementia and traumatic brain injury."Built on Alamar's novel multiplexing technology, the NULISAseq Mouse Panel 120 offers researchers a high-sensitivity, high-throughput solution to uncover complex biological mechanisms. The panel's attomolar (fg/ml) sensitivity and 10 logs of dynamic range allows for the detection of a wide range of proteins found in mouse plasma, even those that are low in abundance, such as p-tau217, from as little as 5 µl sample input.For more information, please visit alamarbio.com.About Alamar Biosciences, Inc.Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease
FREMONT, Calif., March 19, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce the signing of five new distribution partners to expand its global presence. The company has partnered with established industry leaders across key international markets to enhance access to its innovative proteomics technologies.The newly signed distribution partners include:GeneWorks – Australia and New Zealand– and Genomax – Singapore– PhileKorea – South Korea– Scrum Inc. – Japan– Spinco – India"We are excited to welcome these outstanding partners to the Alamar network," said Yuling Luo, Ph.D., Founder, Chairman and CEO of Alamar Biosciences, "Their deep expertise in the life sciences industry and strong regional presence will allow us to bring our next-generation proteomics solutions to more researchers and clinicians worldwide."Alamar's technology empowers scientists to achieve groundbreaking insights in biomarker discovery, drug development, and disease research. Through these new partnerships, researchers in Asia-Pacific will now have enhanced access to Alamar's cutting-edge platforms and technical support.Alamar remains committed to supporting the scientific community with best-in-class tools that enable high-sensitivity protein analysis. For more information on Alamar's distribution network and solutions, visit alamarbio.com.About Alamar Biosciences, Inc.Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA™ Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today
ФРИМОНТ, Калифорния, 25 февраля 2025 г. /PRNewswire/ -- Компания Alamar Biosciences, создающая возможности для использования высокоточной протеомики с целью раннего выявления заболеваний, с гордостью объявляет о начале выпуска набора для разработки индивидуальных анализов NULISAqpcr™, новаторского продукта, который позволит исследователям создавать высокочувствительные и точные анализы биомаркеров, адаптированные к их конкретным исследовательским потребностям, и расширит применение технологии NULISA™ для широкого сообщества исследователей биомаркеров
FREMONT, Kalifornien, 25. Februar 2025 /PRNewswire/ -- Alamar Biosciences, ein Unternehmen, das Präzisionsproteomik zur frühestmöglichen Erkennung von Krankheiten vorantreibt, freut sich, die Markteinführung des NULISAqpcr™ Custom Assay Development Kitankündigen zu können. Dabei handelt es sich ein bahnbrechendes Produkt, das es Forschenden ermöglicht, hochempfindliche und präzise Biomarker-Assays zu erstellen, die auf ihre spezifischen Forschungsbedürfnisse zugeschnitten sind, und die Anwendung der NULISA™-Technologie auf die breitere Biomarker-Forschungsgemeinschaft auszuweiten
FREMONT, Kalifornia, 25 lutego 2025 r. /PRNewswire/ -- Alamar Biosciences, firma tworząca rozwiązania wykorzystywane w proteomice precyzyjnej w celu jak najwcześniejszego wykrywania chorób, z dumą ogłasza premierę NULISAqpcr™ Custom Assay Development Kit - przełomowego produktu umożliwiającego naukowcom tworzenie wysoce czułych i ukierunkowanych testów biomarkerowych, które odpowiadają na specyficzne potrzeby prowadzonych przez nich badań. Tym samym technologia NULISA™ znajdzie szersze zastosowanie w obszarze badań nad biomarkerami